Brought to you by 
Inhale, Pfizer end inhaled insulin deal
04 Dec 2007
Executive Summary
Inhale Therapeutic Systems and Pfizer will collaborate to develop inhalable dry powder insulin products using Inhale's noninvasive pulmonary drug delivery system for macromolecules.
Deal Industry
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Pulmonary
-
Drug Delivery
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Inhale, Pfizer end inhaled insulin deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice